Dissolving Microneedles for Psoriasis: An Intradermal Drug-Exposure Framework for Formulation Design and Clinical Translation

Despite increasing interest in dissolving microneedles (DMNs) for psoriasis therapy, current evaluations often emphasize device performance or therapeutic outcomes rather than drug exposure within target tissues. Psoriasis is a chronic inflammatory skin disease in which achieving sufficient and sustained local drug concentrations remains challenging because of pathological barrier alterations and limitations of conventional topical delivery. DMNs provide a promising minimally invasive approach by enabling direct deposition of therapeutic agents into skin compartments beyond the stratum corneum. This review proposes an exposure-guided framework for evaluating psoriasis-specific DMNs by integrating formulation design, device characteristics, intradermal drug exposure, and therapeutic response. The framework is based on three interconnected dimensions: amount, location, and residence time, which describe the quantity of drug delivered into skin, its spatial distribution within target compartments, and the persistence of local exposure. Current evidence regarding polymer selection, drug-loading strategies, microneedle geometry, and manufacturing processes is critically discussed according to their influence on these exposure-related parameters. Existing studies demonstrate that DMN design strategies can improve drug delivery and therapeutic outcomes; however, quantitative characterization of tissue-specific drug deposition, spatial distribution, and concentration–time profiles remains limited. The proposed framework provides a systematic approach to connect DMN formulation and device optimization with intradermal exposure, local pharmacokinetic/pharmacodynamic (PK/PD) relationships, and clinical translation. Future development of psoriasis-oriented DMNs should incorporate standardized exposure assessment, mechanistic PK/PD evaluation, and human-relevant validation to support rational dose selection and clinical application.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-10-29
DOI
https://doi.org/10.3390/pharmaceutics18111391
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dissolving Microneedles for Psoriasis: An Intradermal Drug-Exposure Framework for Formulation Design and Clinical Translation

Zifan Wang, Jiayinaer Baishan, Mengye Zhan, Qingxu Yang et al.
5 links
Pharmaceutics
Advancements in Transdermal Drug Delivery
article

Dissolving Microneedles for Psoriasis: An Intradermal Drug-Exposure Framework for Formulation Design and Clinical Translation

Zifan Wang, Jiayinaer Baishan, Mengye Zhan, Qingxu Yang, Zhengxian Li, Junjie Fang, Zhenbin Chen
article en

Abstract

Despite increasing interest in dissolving microneedles (DMNs) for psoriasis therapy, current evaluations often emphasize device performance or therapeutic outcomes rather than drug exposure within target tissues. Psoriasis is a chronic inflammatory skin disease in which achieving sufficient and sustained local drug concentrations remains challenging because of pathological barrier alterations and limitations of conventional topical delivery. DMNs provide a promising minimally invasive approach by enabling direct deposition of therapeutic agents into skin compartments beyond the stratum corneum. This review proposes an exposure-guided framework for evaluating psoriasis-specific DMNs by integrating formulation design, device characteristics, intradermal drug exposure, and therapeutic response. The framework is based on three interconnected dimensions: amount, location, and residence time, which describe the quantity of drug delivered into skin, its spatial distribution within target compartments, and the persistence of local exposure. Current evidence regarding polymer selection, drug-loading strategies, microneedle geometry, and manufacturing processes is critically discussed according to their influence on these exposure-related parameters. Existing studies demonstrate that DMN design strategies can improve drug delivery and therapeutic outcomes; however, quantitative characterization of tissue-specific drug deposition, spatial distribution, and concentration–time profiles remains limited. The proposed framework provides a systematic approach to connect DMN formulation and device optimization with intradermal exposure, local pharmacokinetic/pharmacodynamic (PK/PD) relationships, and clinical translation. Future development of psoriasis-oriented DMNs should incorporate standardized exposure assessment, mechanistic PK/PD evaluation, and human-relevant validation to support rational dose selection and clinical application.

PharmaceuticsVol. 18(11)
Northwest Minzu University (CN), Lanzhou University of Technology (CN), State Ethnic Affairs Commission (CN)
National Natural Science Foundation of China, Northwest Minzu University
Good health and well-being
Openalex Percentile: Top 16%
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon